Advances in chemotherapy in advanced non-small-cell lung cancer

Bibliography

• Parkin DM, Bray F, Ferlay J, Global statistics cancer, 2002. CA Cancer J Clin 2005;55:74-108
   PubMed Web of Science ®Google Scholar
• Ries LAG, Eisner MP, Kosary CL, editors. SEER cancer statistics review, Bethesda, MD; 1975 – 2001. National Cancer Institute, 2004. Available from: http://seer.cancer.gov/csr/1975_2001/ [Last accessed 15 May 2010]
   Google Scholar
• Sant M, Aareleid T, Berrino F. EUROCARE-3: survival of cancer patients diagnosed 1990 – 94′results and commentary. Ann Oncol 2003;14(Suppl 5): v61-118
   PubMed Web of Science ®Google Scholar
• Govindan R, Page N, Morgensztern D, Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 2006;24:4539-44
   PubMed Web of Science ®Google Scholar
• Breathnach OS, Freidlin B, Conley B, Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: sobering results. J Clin Oncol 2001;19:1734-42
   PubMed Web of Science ®Google Scholar
• Gridelli C, Ardizzoni A, Douillard JY, Recent issues in first-line treatment of advanced non-small-cell lung cancer: results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology. Lung Cancer 2010;68(3):319-31
   PubMed Web of Science ®Google Scholar
• Sandler A, Gray R, Perry MC, Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-50
   PubMed Web of Science ®Google Scholar
• Reck M, von Pawel J, Zatloukal P, Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 2009;27:1227-34
   PubMed Web of Science ®Google Scholar
• Scagliotti G, Parikh P, von Pawel J, Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage NSCLC. J Clin Oncol 2008;26:3543-51
   PubMed Web of Science ®Google Scholar
• Belani CP, Brodowicz T, Ciuleanu T, Maintenance pemetrexed (Pem) plus best supportive care (BSC) versus placebo (Plac) plus BSC: a randomized phase III study in advanced non-small cell lung cancer (NSCLC) [abstract CRA8000]. J Clin Oncol 2009;27(15S):806s
   Google Scholar
• Cappuzzo F, Coudert B, Wierzbicki R, Overall survival analyses from the SATURN phase III placebo-controlled study of erlotinib as first-line maintenance therapy in advanced non-small-cell lung cancer (NSCLC) [abstract 22LBA]. Eur J Cancer Suppl 2009;7:12
   Google Scholar
• Rosell R, Moran T, Queralt C, Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009;361:958-67
   PubMed Web of Science ®Google Scholar
• Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005;23:1011-27
   PubMed Web of Science ®Google Scholar
• Johnson DH, Fehrenbacher L, Novotny WF, Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004;22:2184-91
   PubMed Web of Science ®Google Scholar
• Akerley WL, Langer CJ, Oh Y, Acceptable safety of bevacizumab therapy in patients with brain metastases due to nonsmall cell lung cancer. J Clin Oncol 2008;26(Suppl): abstract 8043
   PubMedGoogle Scholar
• Ramalingam SS, Dalhberg SE, Langer C, Outcome for elderly advanced non-small cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of the ECOG 4599 study. J Clin Oncol 2008;26:60-5
   PubMed Web of Science ®Google Scholar
• Leighl NB, Zatloukal P, Mezger J, Efficacy and safety of first-line bevacizumab and cisplatin/gemcitabine in elderly patients with advanced non-small cell lung cancer in the B017704 study (AVAiL). J Clin Oncol 2009;27(18S):419s
   Google Scholar
• Shih C, Chen VJ, Gossetti LS, LY231514, a pirrolo[2,3-d]pyrimidine-based antifolate that inhibitsmultiple folate requiring enzymes. Cancer Res 1997;57:1116-23
   PubMed Web of Science ®Google Scholar
• Schultz RM, Chen VJ, Bewley JR, Biological activity of the multitargeted antifolate, MTA (LY231514), in human cell lines with different resistance mechanisms to antifolate drugs. Semin Oncol 1999;26(Suppl 6):68-73
   PubMed Web of Science ®Google Scholar
• Gronberg BH, Bremnes R, Flotten O, Phase III study by the Norwegian Lung Cancer Study Group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2009;27:3217-24
   PubMed Web of Science ®Google Scholar
• Scagliotti G, Hanna N, Fossella F, The differential efficacy of pemetrexed according to NSCLC histology: a review of two phase III studies. Oncologist 2009;14:253-63
   PubMed Web of Science ®Google Scholar
• Hanna N, Shepherd FA, Fossella FV, Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004;22:1589-97
   PubMed Web of Science ®Google Scholar
• Peterson P, Park K, Fossella F, Is pemetrexed more effective in adenocarcinoma and large cell lung cancer than in squamous cell carcinoma? A retrospective analysis of a phase III trial of pemetrexed vs. docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC) [abstract P2-328]. J Thorac Oncol 2007;2(Suppl 4):S851
   Google Scholar
• Gridelli C, Maione P, Rossi A, Potential treatment options after first-line chemotherapy for advanced NSCLC: maintenance treatment or early-second line? Oncologist 2009;14:137-47
   PubMed Web of Science ®Google Scholar
• Grossi F, Aita M, Follador A, Sequential, alternating and maintenance/consolidation chemotherapy in advanced non-small cell lung cancer: a review of the literature. Oncologist 2007;12:451-64
   PubMed Web of Science ®Google Scholar
• Fidias PM, Dakhil SR, Lyss AP, Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 2009;27:591-8
   PubMed Web of Science ®Google Scholar
• Brugger W, Kim JH, Hansen O, Biomarker analyses from SATURN, a phase III placebo-controlled study of erlotinib as first-line maintenance therapy for advanced NSCLC [abstract P-9176]. Eur J Cancer Suppl 2009;7:559
   Google Scholar
• Mok TS, Wu YL, Thongprasert S, Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-57
   PubMed Web of Science ®Google Scholar
• Lee J, Park K, Kim SW, A randomized phase III trial of gefitinib (IRESSA) versus standard chemotherapy (gemcitabine plus cisplatin) as a first-line treatment for never-smokers with advanced ot metastatic adenocarcinoma of the lung [abstract PRS.4]. J Thorac Oncol 2009;4:S283-4
   Web of Science ®Google Scholar
• Mitsudomi T, Morita S, Yatabe Y, Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010;11(2):121-8
   Google Scholar
• Kobayashi K, Inoue A, Maemondo M, First-line gefitinib versus first-line chemotherapy by carboplatin plus paclitaxel in non-small cell lung cancer patients with EGFR mutations: a phase III study (002) by North East Japan Gefitinib Study Group [abstract 8016]. J Clin Oncol 2009;27(18S):415S
   Google Scholar
• Gridelli C, Ciardiello F, Feld R, International multicenter phase III study of first-line erlotinib followed by second-line cisplatin plus gemcitabine versus first-line cisplatin plus gemcitabine followed by second-line erlotinib in advanced non-small cell lung cancer: the TORCH trial [abstract 7508]. J Clin Oncol 2010;28:7s
   Web of Science ®Google Scholar
• Varella-Garcia M, Cho Y, Lu X, ALK gene rearrangements in unselected caucasians with non-small cell lung carcinoma (NSCLC) [abstract 10533]. J Clin Oncol 2010;28:15s
   PubMed Web of Science ®Google Scholar
• Bang Y, Kwak EL, Shaw AT, Clinical activity of the oral ALK inhibitor PF-02341066 in ALK-positive patients with non-small cell lung cancer (NSCLC) [abstract 3]. J Clin Oncol 2010;28:18s
   Web of Science ®Google Scholar
• Pirker R, Pereira JR, Szczesna A, Cetuximab plus chemotherapy in patients with advanced non-smallcell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 2009;373:1525-31
   PubMed Web of Science ®Google Scholar
• Lynch TJ, Patel T, Dreisbach L, Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099. J Clin Oncol 2010;28:911-17
   PubMed Web of Science ®Google Scholar